Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Sigma, Axiogenesis ink marketing agreement
September 2012
SHARING OPTIONS:

ST. LOUIS—Sigma Life Sciences and Axiogenesis have partnered to market mouse induced pluripotent stem (iPS) cell-derived cardiomyocytes and smooth muscle cells for researchers doing long-term studies for the prediction of cardiotoxicity. The cell types are available as ready-to-order cells, application-specific kits and custom services. Sigma Life Sciences' own stem cell product portfolio includes iPS cell CompoZr ZFN-mediated genetic engineering, serum-free cell culture products, cell culture media, 3D matrices, growth factors and antibodies.

"Costly drug candidate failures in clinical trials are most frequently caused by cardiac safety issues. Early identification of these cardiac liabilities is hindered by the lack of reliable and standardized cardiomyocyte cell culture models," John Listello, market segment manager of stem cell research and regenerative medicine at Sigma Life Science, said in a press release.

 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.